Beating Tissue Failure in Oncology
June 4, 2026
By Helen Bristow
A patented AI platform trained on NYU Langone research is predicting cancer mutations from haematoxylin and eosin alone — closing the gap for the 25 percent of patients who never reach molecular testing
5 min read